Biomarkers

Methods in Molecular Biology

Volumn 930, Issue , 2013, Pages 253-273

  Larson, Harmony ^a   Chan, Elena ^a   Sudarsanam, Sucha ^a   Johnson, Dale E ^a  

^a Emiliem Inc   (United States)

Author keywords

Adverse drug reactions; Biological pathways; Biomarkers; Gene ontology; Meta analysis; Pharmacogenomics; Systems biology

Indexed keywords

BIOLOGICAL MARKER;

ADVERSE DRUG REACTION; ANIMAL; ARTICLE; BIOASSAY; GENE REGULATORY NETWORK; HUMAN; METABOLISM; MOUSE; RAT;

ANIMALS; BIOLOGICAL MARKERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDPOINT DETERMINATION; GENE REGULATORY NETWORKS; HUMANS; MICE; RATS;

ANIMALIA;

EID: 84870526481     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-059-5_11     Document Type: Article

References (53)

1. JohnsonDE,SmithDA,ParkBK(2007)Biomarkers: The piece de résistance of innovative medicines. CurrOpin Drug Discov Devel 10:22-24
2. Daly AK (2007) Individualized drug therapy. Curr Opin Drug Discov Devel 10:29-36
3. Walker DB (2006) Serum chemical biomarkers of cardiac injury for nonclinical safety testing. Toxicol Pathol 34:94-104
4. Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3-7
5. Frank R, Hargreaves R (2003) Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2:566-580
6. Johnson DE, Rodgers AD, Sudarsanam S (2006) Future of computational toxicology: Broad application into human disease and therapeutics. John Wiley & Sons, Inc, Hoboken, NJ
7. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93:1054-1061
8. Johnson DE, Smith DA, Park BK (2009) Pharmacogenomics and adverse drug reactions; prospective screening for risk identification. Curr Opin Drug Discov Devel 12:27-30
9. Ingelman-Sundberg M (2008) Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 358:637-639
10. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statininduced myopathy-a genomewide study. N Engl J Med 359:789-799
11. Office of the commissioner safety alerts for human medical products-Phenytoin (marketed as dilantin, phenytek and generics) and fosphenytoin sodium (marketed as Cerebyx and generics), http://www.fda.gov/ Safety/ MedWatch/SafetyInformation/SafetyAlerts forHumanMedicalProducts/ ucm094919.htm
12. Chiao SK, Romero DL, Johnson DE (2009) Current HIV therapeutics: Mechanistic and chemical determinants of toxicity. Curr Opin Drug Discov Devel 12:53-60
13. Bonnet E, Bernard J, Fauvel J, Massip P, Ruidavets J, Perret B (2008) Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients. AIDS Res Hum Retroviruses 24:169-171
14. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Eng J Med 351:2817-2826
15. Wallach I, Jaitly N, Lilien R (2010) A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways. PLoS One 5:e12063
16. Milletti F, Vulpetti A (2010) Predicting polypharmacology by binding site similarity: From kinases to the protein universe. J Chem Inf Model 50:1418-1431
17. Critical Path Institute, http://www.c-path. org/
18. www.pharmaadme.org-Home, http://phar maadme.org/joomla/
19. Genome Canada, http://www.genomecanada.ca/
20. Drug Induced Liver Injury Network-DILIN site, https://dilin.dcri.duke. edu/
21. The pharmacogenomics knowledge base [PharmGKB], http://pharmgkb.org/
22. Waters MD, Fostel JM (2004) Toxicogenomics and systems toxicology: Aims and prospects. Nat Rev Genet 5:936-948
23. Thompson Reuters Genego http://www.genego.com/
24. Ekins S (2006) Systems-ADME/Tox: Resources and network approaches. J Pharmacol Toxicol Methods 53:38-66
25. Davis AP, King BL, Mockus S, Murphy CG, Saraceni-Richards C, Rosenstein M,Wiegers T, Mattingly CJ (2011) The comparative toxicogenomics database: Update 2011. Nucleic Acids Res 39:D1067-D1072
26. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM (2004) Large-scale metaanalysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 101:9309-9314
27. Mattingly CJ, Rosenstein MC, Davis AP, Colby GT, Forrest JN, Boyer JL (2006) The comparative toxicogenomics database: A cross-species resource for building chemical-gene interaction networks. Toxicol Sci 92:587-595
28. The gene ontology, http://www.geneontology.org/
29. GoMiner Home Page, http://discover.nci.nih. gov/gominer/index.jsp
30. Currie RA, Bombail V, Oliver JD, Moore DJ, Lim FL, Gwilliam V, Kimber I, Chipman K, Moggs JG, OrphanidesG(2005) Gene ontology mapping as an unbiased method for identifying molecular pathways and processes affected by toxicant exposure: Application to acute effects caused by the rodent non-genotoxic carcinogen diethylhexylphthalate. Toxicol Sci 86:453-469
31. Yu X, Griffith WC, Hanspers K, Dillman JF, Ong H, Vredevoogd MA, Faustman EM (2006) A system-based approach to interpret dose-and time-dependent microarray data: Quantitative integration of gene ontology analysis for risk assessment. Toxicol Sci 92:560-577
32. Xirasagar S, Gustafson SF, Huang C, Pan Q, Fostel J, Boyer P, Merrick BA, Tomer KB, Chan DD, Yost KJ, Choi D, Xiao N, Stasiewicz S, Bushel P, Waters MD (2006) Chemical effects in biological systems (CEBS) object model for toxicology data, SysTox-OM: Design and application. Bioinformatics (Oxford, England) 22:874-882
33. Mao X, Cai T, Olyarchuk JG, Wei L (2005) Automated genome annotation and pathway identification using the KEGG Orthology (KO) as a controlled vocabulary. Bioinformatics (Oxford, England) 21:3787-3793
34. Hoffmann R, Valencia A (2003) Life cycles of successful genes. Trends Genet 19:79-81
35. Hoffmann R, Valencia A (2003) Protein interaction: Same network, different hubs. Trends Genet 19:681-683
36. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF (2005) A networkbased analysis of systemic inflammation in humans. Nature 437:1032-1037
37. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI (2005) Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYCinteracting genes in human gliomas. Cancer Res 65:8679-8689
38. Reactome, http://www.reactome.org/
39. KEGG: Kyoto encyclopedia of genes and genomes, http://www.genome.jp/kegg/
40. DrugBank: Home, http://www.drugbank.ca/
41. Remm M, Storm CE, Sonnhammer EL (2001) Automatic clustering of orthologs and inparalogs from pairwise species comparisons. J Mol Biol 314:1041-1052
42. Kim DH, Ausubel FM (2005) Evolutionary perspectives on innate immunity from the study of Caenorhabditis elegans. Curr Opin Immunol 17:4-10
43. Kelley BP, Sharan R, Karp RM, Sittler T, Root DE, Stockwell BR, Ideker T (2003) Conserved pathways within bacteria and yeast as revealed by global protein network alignment. Proc Natl Acad Sci USA 100:11394-11399
44. Kharasch ED, Schroeder JL, Bammler T, Beyer R, Srinouanprachanh S (2006) Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A") in rats. Toxicol Sci 90:419-431
45. Duffy CM, Matta BF (2000) Sevoflurane and anesthesia for neurosurgery: A review. J Neurosurg Anesthesiol 12:128-140
46. Bedford RF, Ives HE (2000) The renal safety of sevoflurane. Anesth Analg 90:505-508
47. Vaidya VS, Ferguson MA, Bonventre JV (2008) Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 48:463-493
48. Carlson EA, McCulloch C, Koganti A, Goodwin SB, Sutter TR, Silkworth JB (2009) Divergent transcriptomic responses to aryl hydrocarbon receptor agonists between rat and human primary hepatocytes. Toxicol Sci 112:257-272
49. Chan E, Tan M, Xin J, Sudarsanam S, Johnson DE (2010) Interactions between traditional Chinese medicines and Western therapeutics. Curr Opin Drug Discov Devel 13:50-65
50. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LFA, de Jong D, Van de Vijver MJ, Van't Veer LJ, Peterse JL (2008) Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216:141-150
51. Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: Past, present, and future. Annu Rev Genomics Hum Genet 9:321-345
52. Williams JA, Phillips DH (2000) Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res 60:4667-4677
53. Kretschmer XC, Baldwin WS (2005) CAR and PXR: Xenosensors of endocrine disrupters? Chem Biol Interact 155:111-128